ARST1321, a trial of patients with advanced soft tissue sarcoma, was the first National Clinical Trials Network study codeveloped by pediatric and adult consortia with two treatment cohorts. We report on the findings of a survey to identify barriers to enrolling adolescent and young adult patients (15–39 years) onto the nonchemotherapy arm. The survey response rate was 31% with a 70% completion rate. Common identified reasons for low accrual in order of decreasing frequency included insufficient funding, lack of study awareness or interest, competing trials, toxicity concerns, philosophical differences in the therapy backbone, and regulatory and infrastructure barriers. Clinical Trials.gov ID: NCT02180867.

中文翻译：

---

在儿童肿瘤组研究 ARST1321 的非化疗组中确定了青少年和年轻成人患者的入组挑战

ARST1321 是一项针对晚期软组织肉瘤患者的试验，是第一项由儿科和成人联盟与两个治疗队列共同开发的国家临床试验网络研究。我们报告了一项调查的结果，以确定将青少年和年轻成年患者（15-39 岁）纳入非化疗组的障碍。调查回复率为 31%，完成率为 70%。按频率递减顺序排列的低应计的常见原因包括资金不足、缺乏研究意识或兴趣、竞争性试验、毒性问题、治疗主干的哲学差异以及监管和基础设施障碍。临床 Trials.gov ID：NCT02180867。